Form 4: TENAX Director Proehl Reports New Stock Option Grant

Gerald T. Proehl, a Director and 10% owner of Tenax Therapeutics, Inc., reported the acquisition of 3,000 stock options and updated his beneficial ownership.

Summary

• Gerald T. Proehl, a Director and 10% owner of Tenax Therapeutics, Inc. (TENX), filed a Form 4 reporting changes in beneficial ownership.
• On January 9, 2026, Proehl acquired 3,000 stock options with an exercise price of $13.3 per share, exercisable from January 9, 2027, and expiring on January 9, 2036.
• These new options represent the right to buy 30,000 shares of Common Stock.
• Following this transaction, Proehl directly owns 1,667 shares of Common Stock.
• Proehl's total beneficial ownership of derivative securities includes multiple stock options, a pre-funded warrant for 31,654 shares, and a warrant for 16,660 shares.
• The pre-funded warrant has an exercise price of $0.01 and no expiration date.
• The warrant has an exercise price of $4.5 and will expire on the earlier of 30 trading days following the initial public announcement of topline data from the Phase 3 LEVEL Study (NCT05983250), proportional exercise of the pre-funded warrant, or August 8, 2029.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to a director receiving a new stock option grant, which generally indicates continued alignment of management interests with shareholder value. However, it's a routine filing for insider ownership changes, not a direct financial performance report, hence not strongly positive.

Positives

• A new grant of 3,000 stock options to Director Gerald T. Proehl aligns management incentives with shareholder interests, demonstrating continued commitment to the company's future performance.
• The director's continued significant beneficial ownership, including common stock and various derivative securities, indicates a strong vested interest in the company's success.

Risks

• The expiration of a significant warrant (16,660 shares) is tied to the initial public announcement of topline data from the Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) (NCT05983250), introducing event-driven risk related to clinical trial outcomes.
• The value of the stock options and warrants is dependent on the future stock price of Tenax Therapeutics, Inc., which is subject to market volatility and company performance.

Future Outlook

The company's future outlook is implicitly tied to the progress and results of its clinical trials, specifically the Phase 3 LEVEL Study (NCT05983250), as the expiration of a significant warrant is contingent upon the announcement of its topline data. The new stock option grant provides long-term incentive for the director, aligning with future performance goals.

Industry Context

This filing is a routine disclosure of insider ownership changes, common in the biotechnology and pharmaceutical sectors where executive compensation often includes equity-based incentives like stock options and warrants. The mention of a Phase 3 clinical trial (LEVEL Study) highlights the company's focus on drug development, a high-risk, high-reward endeavor typical of the industry.

Related Party Transactions

• The acquisition of 3,000 stock options by Director Gerald T. Proehl represents a compensation-related transaction between the company and a related party (an insider).

Stakeholder Impact

• Shareholders: The new stock option grant to a director can be viewed positively as it aligns management's long-term interests with shareholder value creation. However, it also represents potential future dilution if options are exercised.
• Investors: Provides transparency into insider holdings and compensation structure, which can influence investment decisions.

Next Steps

• Monitoring the progress and eventual topline data announcement of the Phase 3 LEVEL Study (NCT05983250), which will trigger the expiration of certain warrants.

Key Dates

Recommendation

This Form 4 filing primarily reports a routine insider stock option grant and updates beneficial ownership, which is not typically a standalone catalyst for a strong buy or sell recommendation. While the grant aligns director incentives, it doesn't provide new information on the company's operational or financial performance. The mention of the Phase 3 LEVEL Study and its data announcement as a trigger for warrant expiration highlights a future event that could be price-sensitive, but the filing itself does not provide the results. Therefore, a 'hold' recommendation is appropriate, awaiting more substantive operational or financial news.

Keywords

Tenax Therapeutics, TENX, Form 4, Insider Trading, Stock Options, Warrants, Beneficial Ownership, Director Compensation, SEC Filing, Biotechnology, Pharmaceuticals